Table 1 Characteristics of publications included in this study
Publication | Region | Country | Mean age(cases/controls) | Genotyping method | GDM criteria | Newcastle Ottawa Scale (NOS) |
|---|---|---|---|---|---|---|
Popova 2021 [14] | Europe | Russia | 31.9/29.5 | SNP Genotyping Assay | OGTT | 7 |
Gorczyca 2016 [15] | Europe | Poland | 30.36/30.88 | Sequencing | OGTT | 7 |
Fd 2020 [16] | Europe | Lithuania | 53.1/60.2 | TaqMan allelic discrimination assay | WHO | 8 |
Freathy 2010 [17] | Europe/Pacific | UK and Australia | NA | illumina Golden Gate platform | OGTT | 6 |
Lauenborg 2009 [18] | Europe | Denmark | 43.1/42.5 | TaqMan allelic discrimination assay | OGTT | 6 |
Pagan 2014 [19] | Europe | Spain | 34.31/31.2 | Sequencing | OGTT | 6 |
Papadopoulou 2011 [20] | Europe | Sweden | NA | TaqMan allelic discrimination assay | OGTT | 6 |
Pappa 2011 [21] | Europe | Germany | 32.5/26.67 | PCR | OGTT | 7 |
Shaat 2007 [22] | Europe | Scandinavia | 32.3/30.5 | TaqMan allelic discrimination assay | OGTT | 6 |
Včelák 2012 [23] | Europe | Czech Republic | 32.8/29.9 | TaqMan allelic discrimination assay | WHO | 7 |
Shalabi 2021 [14] | Africa | Egypt | 27.9/27.2 | PCR | OGTT | 8 |
de Melo 2015 [24] | America | Brazil | 32/24 | SNP Genotyping Assay | ADA | 7 |
Huerta 2015 [25] | America | Mexico | 35/28 | SNP genotype (LGC) | OGTT | 6 |
Reyes 2014 [26] | America | Mexico | 29/31 | PCR | ADA | 6 |
Yadav 2016 [27] | Asia | India | 28.12/30.65 | PCR | OGTT | 7 |
Li 2016 [28] | Asia | China | 30.06/28.67 | PCR | OGTT | 7 |
Chen 2019 [29] | Asia | China | 29.9/http: / /grch37. ensembl. org /index. Html | PCR | OGTT | 8 |
Chen 2019 [30] | Asia | China | 28.7/29.5 | PCR | OGTT | 8 |
Aris 2011 [31] | Asia | Malaysia | 29.7/28.5 | NA | ADA | 6 |
Cho 2009 [32] | Asia | Korea | 32/64.7 | Allelic discrimination assay | IWCGDM | 6 |
Kan 2014 [33] | Asia | China | 30.7/30.9 | Allecic discrimination assay | OGTT | 6 |
RIZK 2011 [34] | Asia | Qatar | NA | TaqMan allelic discrimination assay | OGTT | 6 |
Shi 2014 [35] | Asia | China | 30/29 | AS-PCR | OGTT | 7 |
Thomas 2014 [36] | Asia | India | NA | NA | NA | 6 |
Zhang 2015 [37] | Asia | China | 30.58/28.75 | PCR-LDR | OGTT | 7 |
Klein 2012 [38] | Pacific | Australia | 28.2/30.1 | NA | OGTT | 6 |
Isfer 2017 [39] | America | Brazil | 30.6/31.9 | PCR | ADA | 8 |
Stuebe 2014 [40] | America | USA | 24.1(toal) | Sequenom Iplex platform | OGTT | 7 |
Li 2016 [41] | Asia | China | 35.50/28.81 | PCR | OGTT | 8 |
Watanabe 2007 [42] | America | USA | 30.58/28.75 | PCR–RFLP | OGTT | 6 |
Ye 2016 [43] | Asia | China | 28.9/29.2 | SNP genotype (LGC) | OGTT | 7 |
Hui 2011 [44] | Asia | China | 32/30 | PCR-LDR | OGTT | 6 |
Liu 2014 [45] | Asia | China | 32.5/29.9 | PCR | OGTT | 6 |
Imran 2014 [46] | Asia | India | 26.7/24 | PCR | OGTT | 6 |
Shaat 2005 [47] | Europe | Sweden | 32.2/30.5 | SNP genotype (LGC) | OGTT | 5 |
Anna 2018 [48] | America | Mexico | 32.13/30.63 | TaqMan qPCR assay | OGTT | 8 |
Ustianowski 2021 [49] | Europe | Poland | 30.3/31.7 | PCR | OGTT | 8 |
Zhang 2019 [50] | Asia | China | 28.2/27.5 | PCR | OGTT | 8 |